BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24625004)

  • 41. Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4.
    Yu S; Asa SL; Weigel RJ; Ezzat S
    J Biol Chem; 2003 May; 278(22):19597-602. PubMed ID: 12642581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
    Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
    Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
    Zhang P; Zhang H; Wang Y
    Cell Tissue Res; 2021 Feb; 383(2):865-879. PubMed ID: 33151453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
    Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
    Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
    Marmé F; Hielscher T; Hug S; Bondong S; Zeillinger R; Castillo-Tong DC; Sehouli J; Braicu I; Vergote I; Isabella C; Mahner S; Ferschke I; Rom J; Sohn C; Schneeweiss A; Altevogt P
    Int J Cancer; 2012 Aug; 131(4):E586-91. PubMed ID: 22034009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.
    Riebold M; Kozany C; Freiburger L; Sattler M; Buchfelder M; Hausch F; Stalla GK; Paez-Pereda M
    Nat Med; 2015 Mar; 21(3):276-80. PubMed ID: 25665180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development.
    Naidu R; Har YC; Taib NA
    Oncol Res; 2009; 18(2-3):65-71. PubMed ID: 20066896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gender-Specific Association Between FGFR4 Gly388Arg Gene Variants and Hypertension.
    Al-Daghri NM; Mohammed AK; Al-Attas OS; Draz HM; Alokail MS
    Genet Test Mol Biomarkers; 2017 Jul; 21(7):422-427. PubMed ID: 28650667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.
    Huang X; Yang C; Jin C; Luo Y; Wang F; McKeehan WL
    Mol Carcinog; 2009 Jun; 48(6):553-62. PubMed ID: 19009564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
    Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
    PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
    Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
    Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.